Behind the Study: Retaining Nanomolar Potency in Lung Cancer
August 16, 2021
Dr. Aditya Kulkarni discusses a study he co-authored, published by Oncotarget in 2021, and entitled, “The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations.” continue reading »